Think of Enterprise Value as the theoretical takeover price. It is more comprehensive than market capitalization (Market Cap), which only includes common equity. Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
EV-to-EBIT is calculated as Enterprise Value divided by its EBIT. As of today, Pure Biologics's Enterprise Value is zł41.32 Mil.
Pure Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 was zł-6.58 Mil. Therefore, Pure Biologics's EV-to-EBIT ratio for today is -6.28.
EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA. As of today, Pure Biologics's Enterprise Value is zł41.32 Mil.
Pure Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 was zł-6.47 Mil. Therefore, Pure Biologics's EV-to-EBITDA ratio for today is -6.38.
EV-to-Revenue is calculated as Enterprise Value divided by its Revenue. As of today, Pure Biologics's Enterprise Value is zł41.32 Mil.
Pure Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 was zł0.00 Mil. Therefore, Pure Biologics's EV-to-Revenue ratio for today is .
EV-to-FCF is calculated as Enterprise Value divided by its Free Cash Flow. As of today, Pure Biologics's Enterprise Value is zł41.32 Mil.
Pure Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 was zł-8.63 Mil. Therefore, Pure Biologics's EV-to-FCF ratio for today is -4.79.
*** Please note that the current Enterprise Value is calculated using the current market capitalization and the most recently available financial data. If key financial fields—Long-Term Debt & Capital Lease Obligation and Short-Term Debt & Capital Lease Obligation—are recorded as null in the latest reporting period, our data vendor will default to using data from the prior period with valid entries.
Pure Biologics (WAR:PUR) Enterprise Value Explanation
When an investor buy a company, the investor needs to pay not only the common shares, he/she also needs to pay the shareholders of Preferred Stocks. He also assumes the debt of the company, and receives the cash on the company's balance sheet.
If a company has more cash than debt, the investor actually pays less than the Market Cap because he immediately owns the cash once the transaction goes through.
The market value of Preferred Stock needs to be added to the market value of common stocks in the calculation of Enterprise Value.
For the companies with the same Market Cap, the smaller the Enterprise Value is, the cheaper the company is.
Enterprise Value can be negative when the company's net cash is more than its Market Cap. In this case the investor is basically getting the company for free and get paid for that.
1. EV-to-EBIT is calculated as Enterprise Value divided by its EBIT.
Pure Biologics's current Enterprise Value is zł41.32 Mil.
Pure Biologics's EBIT for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-6.58 Mil.
2. EV-to-EBITDA is calculated as Enterprise Value divided by its EBITDA.
Pure Biologics's current Enterprise Value is zł41.32 Mil.
Pure Biologics's EBITDA for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-6.47 Mil.
Pure Biologics's current Enterprise Value is zł41.32 Mil.
Pure Biologics's Revenue for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł0.00 Mil.
Pure Biologics's current Enterprise Value is zł41.32 Mil.
Pure Biologics's Cash Flow from Operations for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-8.63 Mil.
Pure Biologics's current Enterprise Value is zł41.32 Mil.
Pure Biologics's Free Cash Flow for the trailing twelve months (TTM) ended in Mar. 2026 adds up the quarterly data reported by the company within the most recent 12 months, which was zł-8.63 Mil.
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pure Biologics Enterprise Value Related Terms
Pure Biologics Enterprise Value Historical Data
* Premium members only.
The historical data trend for Pure Biologics's Enterprise Value can be seen below:
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
WAR:PUR vs VRTX, REGN, ALNY: Enterprise Value Comparison
For the Biotechnology subindustry, Pure Biologics's Enterprise Value, along with its competitors' market caps and Enterprise Value data, can be viewed below:
* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.
Pure Biologics Enterprise Value vs Biotechnology Industry
For the Biotechnology industry and Healthcare sector, Pure Biologics's Enterprise Value distribution charts can be found below:
* The bar in red indicates where Pure Biologics's Enterprise Value falls into.
Enterprise Value is calculated as the market cap plus debt and minority interest and preferred shares, minus total cash, cash equivalents, and marketable securities.
Pure Biologics's Enterprise Value for the fiscal year that ended in Dec. 2025 is calculated as
* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD. * For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.
Pure Biologics (WAR:PUR) has a Enterprise Value of zł41.32 Mil as of Jul. 04, 2026. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pure Biologics and its competitors.
Is Pure Biologics' Enterprise Value too high?
Pure Biologics' current Enterprise Value is zł41.32 Mil. Overall, Pure Biologics has a GF Score™ of 19/100, reflecting its overall financial health beyond just this single metric.
How does Pure Biologics' Enterprise Value compare to VRTX and REGN?
Pure Biologics' Enterprise Value of zł41.32 Mil can be compared against companies in the Biotechnology industry. See the competitive comparison table and distribution chart on this page for a detailed peer-by-peer breakdown.
What is a good Enterprise Value for a Biotechnology company?
A good Enterprise Value depends on the Biotechnology industry context. However, Enterprise Value should not be evaluated in isolation — investors should consider it alongside profitability, growth, and financial strength metrics. Use the industry distribution chart on this page to see where any company falls relative to its peers.
What does a high Enterprise Value mean?
A high Enterprise Value can signal that a stock is expensive relative to its fundamentals. Enterprise value equals the sum of market cap, debt and preferred shares less cash and equivalents. View historical data on Pure Biologics and its competitors. Pure Biologics's current Enterprise Value is zł41.32 Mil. However, context matters — high-growth companies often justify higher valuations. Always evaluate alongside other metrics like GF Score™ and GF Value™.
Is Pure Biologics stock overvalued right now?
Pure Biologics (WAR:PUR) has a current Enterprise Value of zł41.32 Mil. The current Enterprise Value is zł41.32 Mil. Pure Biologics' overall GF Score™ is 19/100 with 2 warning signs to review. Investors should evaluate multiple metrics — including profitability, growth, and financial strength — before making a decision.
How is Enterprise Value calculated?
Enterprise Value is calculated from a company's financial statements. For Pure Biologics (WAR:PUR), the current Enterprise Value is zł41.32 Mil as of Jul. 04, 2026. GuruFocus calculates this using data sourced from SEC filings and annual reports. See the calculation section and 30-year financial data on this page for the full breakdown.
Pure Biologics SA is a Poland based biopharmaceutical company. It invests in the development of new, innovative (non-generic or biosimilar) biological drugs, medical and diagnostic products. It is mainly engaged in the research and development of the biologically active molecule in the drug development process. It specializes in the production and analysis of recombinant proteins and antibodies, contract studies of early product development phases, protein engineering, protein formulation, genomic sequencing, proteomics analysis and bioinformatics. Its projects include cancer immunotherapy, therapy of neurodegenerative diseases, diagnosis of tumors, and other partner projects.
19GF Score
Get the complete analysis for WAR:PUR
Enterprise Value is just one metric. See GF Value™, 30-year financials, guru trades, warning signs, and more.
Quick Browse
Personalize
Premium Gurus 
Create New Portfolio
WAR:PUR has been successfully added to your 
